Patent SG-11201908056Q-A (SG)
Title: Anti-par2 antibodies and uses thereof
Inventor: DOBSON CLAIRE
IPC: A61P25/00
Filed: 2018-03-16
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 September 2018 (20.09.2018) WIPO I PCT omit VIII °nolo VIII ioo Ill mom OII iflo oimIE (10) International Publication Number WO 2018/167322 Al (51) International Patent Classification: C07K 16/28 (2006.01) A61K 39/00 (2006.01) A61P 25/00 (2006.01) (21) International Application Number: PCT/EP2018/056776 (22) International Filing Date: 16 March 2018 (16.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/472,462 16 March 2017 (16.03.2017) US 62/637,766 02 March 2018 (02.03.2018) US (71) Applicant: MEDIMMUNE LIMITED [GB/GB]; Mil- stein Building Granta Park, Cambridge CB21 6GH (GB). (72) Inventors: DOBSON, Claire; Milstein Building Granta Park, Cambridge CB21 6GH (GB). WILLIAMS, Richard; Milstein Building Granta Park, Cambridge CB21 6GH (GB). GURRELL, Ian; Milstein Building Granta Park, Cambridge CB21 6GH (GB). PODICHETTY, Sadhana; Milstein Building Granta Park, Cambridge CB21 6GH (GB). FAIRMAN, David; Milstein Building Granta Park, Cambridge CB21 6GH (GB). THORNTON, Peter; Mil- stein Building Granta Park, Cambridge CB21 6GH (GB). NEWTON, Philip; Milstein Building Granta Park, Cam- bridge CB21 6GH (GB). (74) Agent: RASHID, Jeremy et al.; 5 Old Broad Street, Lon- don EC2N 1DW (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, N 00 (54) Title: ANTI-PAR2 ANTIBODIES AND USES THEREOF 0 (57) : The present disclosure provides antibodies and antigen-binding fragments capable of binding PAR2. In some embodi- \" ments, the anti-PAR2 antibodies or antigen-binding fragments thereof bind PAR2 in a pH-dependent manner. The disclosure further 0 provides methods for making and using the antibodies and antigen-binding fragments.